Individualization of antihypertensive drug treatment

Diabetes Care

Volumn 36, Issue SUPPL.2, 2013, Pages

  Mancia, Giuseppe ^a   Grassi, Guido ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RAMIPRIL; RENIN INHIBITOR; TRIACYLGLYCEROL;

AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG COST; DRUG TOLERABILITY; DYSLIPIDEMIA; ETHNIC DIFFERENCE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART INJURY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY INJURY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; PLASMA RENIN ACTIVITY; PREGNANT WOMAN; RENAL PROTECTION; RISK REDUCTION; SEX DIFFERENCE; SODIUM INTAKE; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; INDIVIDUALITY; INDIVIDUALIZED MEDICINE; PATIENT-CENTERED CARE; RISK FACTORS;

EID: 84891777978     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS13-2013     Document Type: Article

References (67)

1. World Health Organization. Arterial Hypertension. Report of a WHO Expert Committee. Geneva, World Health Org., 1978
2. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427
3. Turnbull F, Neal B, Ninomiya T, et al.; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-1123
4. Law MR, Morris JK, Wald NJ. Useofblood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemio-logical studies. BMJ 2009;338:b1665
5. Mancia G, Laurent S, Agabiti-Rosei E, et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-2158
6. Turnbull F, Woodward M, Neal B, et al.; Blood Pressure Lowering Treatment Trialists' Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 2008;29:2669-2680
7. Bos-Thompson MA, Hillaire-Buys D, Muller F, et al. Fetal toxic effects of an-giotensin II receptor antagonists. Case report and follow-up after birth. Ann Pharmacol 2005;39:157-161
8. National Institute for Health and Clinical Excellence (NICE). Hypertension: clinical management of primary hypertension in adults. Clinical guidelines, CG127 [article online] 2011. Available from www.nice.org.uk/ guidance/CG127. Accessed 20 December 2012
9. Beckett NS, Peters R, Fletcher AE, et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898
10. Chobanian AV, Bakris GL, Black HR, et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572
11. Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED, Jr. Renin, angio tensin and aldosterone system in pathogenesis and management of hyper tensive vascular disease. Am J Med 1972; 52:633-652
12. Stanton AV, Dicker P, O'Brien ET. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high-and low-baseline PRA levels, respectively. Am J Hypertens 2009; 22:954-957
13. Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25: 1105-1187
14. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998;31:68-72
15. Grassi G, Vailati S, Bertinieri G, et al. Heart rate as marker of sympathetic activity. J Hypertens 1998;16:1635-1639
16. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283: 1967-1975
17. Saino A, Pomidossi G, Perondi R, et al. Intracoronary angiotensin II potentiates coronary sympathetic vasoconstriction in humans. Circulation 1997;96:148-153
18. Ferrario CM. Neurogenic actions of an-giotensin II. Hypertension 1983;5:V73-V79
19. Mancia G, Bombelli M, Corrao G, et al. Metabolic syndrome in the Pressioni Ar-teriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007;49:40-47
20. Kannel WB, Vasan RS. Assessment of cardiovascular risk and choice of antihy-pertensive therapy. Curr Hypertens Rep 2004;6:346-351
21. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365: 1415-1428
22. Volpe M, Tocci G, Trimarco B, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007;25:1491-1498
23. Mancia G, Facchetti R, Bombelli M, et al. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005;45:1072-1077
24. Pesant Y, Marc-Aurèle J, Bielmann P, et al. Metabolic and antihypertensive effects of nebivolol and atenolol in normo-metabolic patients with mild-to-moderate hypertension. Am J Ther 1999;6:137-147
25. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the An-tihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003;21: 1563-1574
26. Wagner A, Sadoun A, Dallongeville J, et al. High blood pressure prevalence and control in a middle-aged French population and their associated factors: the MONA LISA study. J Hypertens 2011;29: 43-50
27. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006;24:3-10
28. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207
29. Gerstein HC, Yusuf S, Bosch J, et al.; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosigli-tazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-1105
30. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991;14:203-209
31. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renon-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005;23:463-473
32. Agabiti Rosei EA, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007;67:1097-1107
33. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR; SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005;95:29-35
34. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41-46
35. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on pro-teinuria in renal disease. Ann Intern Med 2008;148:30-48
36. Rehman A, Schiffrin EL. Vascular effects of antihypertensive drug therapy. Curr Hypertens Rep 2010;12:226-232
37. Foster MC, Hwang SJ, Larson MG, et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med 2007;167:1386-1392
38. Bombelli M, Facchetti R, Carugo S, et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens 2009;27:2458-2464
39. Rizzoni D, Porteri E, Boari GE, et al. Prognostic significance of small-artery structure in hypertension. Circulation 2003;108:2230-2235
40. Haller H, Ito S, Izzo JL Jr, et al.; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type2diabetes. N Engl J Med 2011;364: 907-917
41. Okin PM, Devereux RB, Jern S, et al.; LIFE Study Investigators. Regression of elec-trocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-2349
42. Schmieder RE, Mann JF, Schumacher H, et al.; ONTARGET Investigators. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011;22:1353-1364
43. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004;292:2350-2356
44. Zanchetti A, Bond MG, Hennig M, et al.; European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002;106:2422-2427
45. Zanchetti A, Hennig M, Hollweck R, et al. Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation 2009; 120:1084-1090
46. Costanzo P, Perrone-Filardi P, Vassallo E, et al. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. J Am Coll Cardiol 2010;56:2006-2020
47. Turnbull F, Neal B, Algert C, et al.; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165:1410-1419
48. Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304: 61-68
49. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al.; INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816
50. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259
51. Yusuf S, Teo KK, Pogue J, et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559
52. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462
53. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
54. Lewis EJ, Hunsicker LG, Clarke WR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartanin patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860
55. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413-1418
56. Parving HH, Brenner BM, McMurray JJ, et al.; ALTITUDE Investigators. Car-diorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204-2213
57. Flather MD, Shibata MC, Coats AJS, et al.; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26: 215-225
58. Packer M, Bristow MR, Cohn JN, et al.; U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355
59. Pitt B, Zannad F, Remme WJ, et al.; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717
60. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin IIdrenin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982;4:966-972
61. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-930
62. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-1553
63. Dahlöf B, Sever PS, Poulter NR, et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bend-roflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366: 895-906
64. Mancia G, Zanchetti A; European Society of Hypertension-European Society of Cardiology. Choice of antihypertensive drugs in the European Society of Hypertension-European Society of Cardiology guidelines: specific indications rather than ranking for general usage. J Hypertens 2008;26:164-168
65. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-1310
66. Ambrosioni E, Leonetti G, Pessina AC, Rappelli A, Trimarco B, Zanchetti A; Scientific Committee of the Italian Pharma-coepidemiological Survey on Antihy pertensive Therapy. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on an-tihypertensive therapy. J Hypertens 2000; 18:1691-1699
67. Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011;29:610-618